Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Risedronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 12/20 | 0.97 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.97 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Risedronic Acid SCHEMBL29362587 | 0.98 | FDPS (1.00) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL18378 | 0.98 | FDPS (1.00) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL4989214 | 0.97 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL2115050 | 0.97 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL3170751 | 0.97 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL2115054 | 0.97 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL22720090 | 0.95 | FDPS (0.94) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL22720092 | 0.95 | FDPS (0.94) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL4643040 | 0.90 | FDPS (0.83) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| SCHEMBL10001488 | 0.89 | FDPS (0.82) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1243592-B1 | A process for the preparation of risedronic acid | ADAMED SP ZOO (PL) | 2005-06-08 | — | — | EP | claimed |
| EP-1243592-A2 | A process for the preparation of risedronic acid | Adamed SP. Z O.O. (PL) | 2002-09-25 | — | — | EP | claimed |
| US-20100317859-A1 | Process for the Preparation of Risedronate Sodium | ACTAVIS GROUP PTC EHF (IS) | 2010-12-16 | — | — | US | disclosed |
| US-20090149427-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS AND HYDRATES OF RISEDRONIC ACID | PLIVA HRVATSKA D.O.O. | 2009-06-11 | — | — | US | disclosed |
| EP-2018392-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS AND POLYMORPHIC FORMS | Pliva Hrvatska D.O.O. (HR) | 2009-01-28 | — | — | EP | disclosed |
| WO-2008152518-A2 | PROCESS FOR THE PREPARATION OF RISEDRONIC ACID OR RISEDRONATE SODIUM | ACTAVIS GROUP PTC EHF (IS) | 2008-12-18 | — | — | WO | disclosed |
| EP-1928889-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS AND HYDRATES OF RISEDRONIC ACID | Pliva Hrvatska D.O.O. (HR) | 2008-06-11 | — | — | EP | disclosed |
| WO-2008040993-A1 | PHARMACEUTICAL FORMULATION OF RISEDRONATE | PLIVA HRVATSKA D.O.O. (HR) | 2008-04-10 | — | — | WO | disclosed |
| EP-1888606-A2 | PROCESS AND NOVEL SALT | PLIVA HRVATSKA d.o.o. (HR) | 2008-02-20 | — | — | EP | disclosed |
| WO-2007132138-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS AND POLYMORPHIC FORMS | PLIVA HRVATSKA D.O.O. (HR) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007036688-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS AND HYDRATES OF RISEDRONIC ACID | PLIVA HRVATSKA D.O.O. (HR) | 2007-04-05 | — | — | WO | disclosed |
| WO-2006129056-A2 | PROCESS AND NOVEL SALT | PLIVA HRVATSKA D.O.O (HR) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317859-A1 | Process for the Preparation of Risedronate Sodium | PPIP5K2, PDE8B, HMGCR | FDPS 23/4885BTN3A1 4441/4885PDE3A 379/4885 |
| US-20090149427-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS AND HYDRATES OF RISEDRONIC ACID | SLC5A6, SLC26A4, SLC6A6 | FDPS 443/4885BTN3A1 3653/4885PDE3A 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.